HERPLEX
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Jun 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HERPLEX is an ophthalmic solution approved in 1963 for the treatment of herpes simplex keratitis and other viral eye infections. As a small-molecule topical antiviral, it works by inhibiting viral replication in ocular tissues. The product represents a legacy therapeutic option in the ophthalmic antiviral space.
LOE Approaching
Product nearing loss of exclusivity with moderate competitive pressure (30/100), suggesting a contracting team and shift toward generic transition planning and cost management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HERPLEX offers limited career growth but valuable experience in mature product management, cost containment, and LOE strategy—key skills for managing portfolio transitions. Roles are primarily defensive, focused on revenue protection and generic transition planning rather than growth initiatives.
Brand ManagerCommercial Operations Manager
Worked on HERPLEX at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.